Linear DNA Archives

Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program

Applied DNA Announces Joint Development Agreement to Integrate Linea™ IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow

APDN Announces Receipt of Linea™ DNA Follow-On Order for Cancer Diagnostic Application

Applied DNA Extends Application of Linea™ IVT Platform to saRNA (self-amplifying mRNA)

APDN Announces Receipt of Largest Single Purchase Order for LinearDNA™ To-Date

LinearDNA™ Platform Development Milestone: First Successful Administration of LinearDNA In Vivo via Lipid Nanoparticles (LNP)

The Future of RNA Therapies Produced with LinearDNA™ IVT Templates

APDN Launches Initiatives to Expand Awareness of LinearDNA™ Platform as an Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website

Positive Preclinical Data for LinearDNA™ as Novel Cancer Vaccine Strategy

Spindle Biotech Research Collaboration on mRNA Production System

Beefing Up Cancer Treatments, With A Vaccine In Sight

LineaRx Receives Repeat Orders for LinearDNA

Research Publication Demonstrates Utility of APDN’s LinearDNA™ in Non-Viral CAR T Manufacturing

APDN, Evvivax Announce LinearDNA™ Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines

Clinical Trial to Evaluate LinearDNA COVID-19 Vaccine Candidate for Felines

APDN Develops Linear DNA Veterinary COVID-19 Vaccine

APDN Announces Linear DNA Orders from New Contract Research Customers for Use in RNA Vaccine and Adeno-Associated Virus Applications

APDN Secures Grant from National Grid Partnered with the New York State MEP to Support Manufacture of COVID-19 Diagnostic Kits and Vaccine Candidates

APDN Provides Update on Linear-DNA COVID-19 Vaccine Candidates Development Program

APDN to Participate in Maxim Group’s COVID-19 Virtual Conference Series on May 27

APDN and Takis Biotech Announce the Production of Neutralizing Antibodies Against SARS-CoV-2 After DNA Vaccination in Animals

Italian Biotech Startup Racing To Develop A Coronavirus Vaccine

APDN High-Sensitivity and High-Throughput COVID-19 Diagnostic Kit Enters Validation Process in Partnership with Stony Brook University Hospital

LI Biotech Speeds COVID-19 Vaccine Candidates To Italy

APDN Ships COVID-19 LinearDNA™ Vaccine Candidates to Italian Development Partner to Begin Preclinical Animal Testing

APDN to Speak on COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference on May 5

APDN Ships LinearDNA™ to Another Development Customer

APDN Secures Top-20 Pharmaceutical Manufacturer as Drug Development Customer

APDN Leverages COVID-19 Vaccine Development and Proprietary Linear DNA Manufacturing Capability to Design a High Sensitivity Diagnostic Kit for Virus Detection

APDN COVID-19 Collaboration Partner Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of a Vaccine Candidate on Pre-Clinical Models

Stony Brook firm working on coronavirus vaccine

Applied DNA, Takis Biotech design four Covid-19 vaccine candidates

Applied DNA Speeds Coronavirus Vaccines Toward Tests

APDN Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine Candidates Designed

Applied DNA To Speed Up Coronavirus Countermeasures

Applied DNA, Takis Biotech partner on coronavirus vaccine

LineaRx and Takis Biotech Collaborate for Development of a Linear DNA Vaccine Candidate Against Wuhan Coronavirus 2019-nCoV

LineaRx, Inc. Signs Licensing Agreement with LifeSensors

APDN to Hold Investment Community Meetings During the JP Morgan 38th Annual Healthcare Conference and Present at the Biotech Showcase 2020

LineaRx signs agreement with TYME Technologies

LineaRx Signs Agreement with TYME Technologies for Functional ICTC Assay Services in Pancreatic Cancer Trial

APDN Reports 14 Development Customers for its Linear DNA Manufacturing Platform

iCTC Platform Shows Superior Correlation over PSA as a Biomarker

Linear DNA Combo Shows Punch In Cancer Fight

LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction

For Applied DNA, New Blood — And A Shot In The Arm

Medicare Coverage of CAR T-Cell Therapy Holds Positive Implications for LineaRx

LineaRx Acquires Cancer Cell Assets and Intellectual Property of Vitatex

LineaRx Acquires Assets and Intellectual Property of Vitatex

LineaRx Receives Multiple Orders for Linear DNA for Use in Therapeutic Development

LineaRx to Support Therapy Development for Neurodegenerative Diseases

LineaRx Anticipates Expansion in Diagnostics Market

LineaRx Achieves Higher Expression and Survival Rates in Human T Cells

Linear DNA Crosses the Line between Tags and Therapeutics

LineaRx Achieves Anti-CD19 Expression in Human CAR T Cells via Plasmid-Free Platform

LineaRx and Takis/Evvivax Progress Linear DNA for Use as Cancer Vaccine Candidates

LineaRx to Announce DNA Vaccine Preclinical Data and Efficacy of In-Licensed CAR T Therapy

LineaRx Provides Cost and Quality Advantages to Technogenetics

At LineaRX, Putting The Horsepower Behind The CAR T

Non-Viral, Plasmid-Free CAR T-Manufacturing Platform Begins Preclinicals

LineaRx Licenses CAR T Drug Candidate, Initiates Pre-Clinical Development of Non-viral, Plasmid-free CAR T Manufacturing Platform

LineaRx Secures New RNA Therapeutics Customers for Contract Research Services

LineaRx to Collaborate with Italian Companies Takis and Evvivax on Cancer Vaccines

LineaRx Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines

With New Spinoff, Biotech Goes All-In On DNA Sales

APDN Forms Subsidiary, LineaRx, to Develop DNA for Biotherapeutics

APDN Presenting Linear DNA for Gene Therapy at Boston Immuno-Oncology Summit

Recent Press Releases